Skip to main content
Premium Trial:

Request an Annual Quote

Lantern Pharma Begins Trial of DNA Damaging Agent LP-284 in Lymphomas, Certain Solid Tumors

NEW YORK – Lantern Pharma said on Friday it began treating patients in a Phase I clinical trial of its investigational DNA damaging agent LP-284 in patients with relapsed or refractory non-Hodgkin lymphoma and certain solid tumors.

The Phase I, first-in-human trial will include 110 patients with non-Hodgkin lymphoma, including mantle cell lymphoma, double-hit lymphoma, and other high-grade B-cell lymphomas, as well as other select solid tumors and sarcomas. In the study, the company hopes to determine the maximum tolerated dose and the recommended Phase II dose for LP-284 as well as assess its pharmacokinetics and efficacy.

The Phase Ia portion of the study will include up to 30 patients, depending on the number of dose levels evaluated. In the Phase Ib portion, researchers will enroll up to 40 patients each in two cohorts for mantle cell lymphoma and high-grade B-cell lymphomas.

"We believe LP-284 has unique and breakthrough potential for patients with relapsed or refractory lymphomas and certain solid tumors with certain genomic signatures, many of which have no or limited effective therapeutic options," Lantern CEO Panna Sharma said in a statement.

Lantern, based in Dallas, developed LP-284 using RADR, its artificial intelligence and machine learning platform, which stands for Response Algorithm for Drug Positioning & Rescue. According to Sharma, the platform helped researchers better understand LP-284's mechanism of action and aided in "identifying and prioritizing its cancer indications and generating machine learning biomarker signatures to assist with patient selection in future clinical trials."

LP-284 is Lantern's second DNA damaging agent to enter clinical trials. Last year, it began a Phase I trial of LP-184 in patients with certain solid tumors, including those with DNA damage response (DDR) deficiencies. The firm's lead candidate, LP-300, is being studied with chemotherapy in non-small cell lung cancer patients whose tumors harbor alterations in MET exon 14, ALK, EGFR, or NTRK.